Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plonmarlimab (TJ003234) in Severe COVID-19
NCT04341116Phase 3Completed
- Sponsor
- I-Mab
- Start
- Apr 2020
- Primary completion
- Feb 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of plonmarlimab in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by I-Mab. Primary endpoint: Percentage of Subjects Alive and Free of Mechanical Ventilation Among Subjects Who Are Free of Mechanical Ventilation at Baseline at Day 30. Started Apr 2020; status: completed.
02
Drugs
plonmarlimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04341116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04341116.